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Obesity has been associated with an increased risk of osteoarthritis (OA). However, the mechanism by which obesity contributes to OA
remains uncertain. Adiponectin, an adipocyte-derived hormone, has shown anti-diabetic and anti-atherogenic properties. In the present study, we
aimed to investigate the potential role of adiponectin in OA disease. We demonstrated that adiponectin was present in OA synovial fluid (SF) and
its expression level was almost 100-fold decrease compared with that in OA plasma. FPLC and ELISA studies revealed the distribution and
abundance of the adiponectin complexes in plasma and SF from patients with OA. The percentage of high molecular weight (HMW) per total
adiponectin in OA SF was lower than in OA plasma, while that of the hexamer form was similar and the trimer form was higher. The expression
levels of adiponectin receptors AdipoR1 and AdipoR2 were examined in human OA tissues by RT-PCR. AdipoR1 was abundantly expressed in
cartilage, bone and synovial tissues, whereas AdipoR2 was rarely detected. Finally, the effects of adiponectin on primary chondrocyte functions
were studied by using antibody-based protein array and RT-PCR. The patterns of mRNA expression and protein production strongly indicate that
adiponectin is involved in the modulation of cartilage destruction in chondrocytes by up-regulating TIMP-2 and down-regulating IL-1β-induced
MMP-13. Together these findings clearly indicate that the adiponectin may act as a protective role in the progression of OA, and this also provide
new thinking on the relationship between obesity and OA.
© 2006 Elsevier B.V. All rights reserved.Keywords: Adiponectin; Osteoarthritis; MMP-131. Introduction
Adiponectin is a newly discovered cytokine that is secreted
by adipose tissue [1,2]. It is abundantly present in the circulation
in three molecular forms: trimer, hexamer, and a high molecular
weight (HMW) species [3]. Early studies have suggested that
adiponectin plays a key role in the control of energy
homeostasis because its plasma levels are inversely correlated
with body mass index (BMI), intra-abdominal fat, and indices
of insulin resistance [4,5]. In addition, the reciprocal association
of adiponectin and C-reactive protein levels in both human⁎ Corresponding author. Fax: +886 2 2737 5618.
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doi:10.1016/j.bbadis.2006.06.008plasma and adipose tissues has been described, suggesting that
adiponectin may participate in the development of athero-
sclerosis [6]. Two adiponectin receptors, AdipoR1 and
AdipoR2, have recently been cloned from both human and
murine tissues. AdipoR1 is abundantly expressed in skeletal
muscle, whereas AdipoR2 is predominantly expressed in the
liver [7]. AdipoR1 and AdipoR2 are predicted to contain seven
transmembrane domains, but are structurally and functionally
distinct from G-protein-coupled receptors. Studies have also
indicated that AdipoR1 and AdipoR2 may be able to form
homo- and hetero-multimers [8,9]. Another receptor, the more
recently reported T-cadherin, has been shown to bind the
hexamer and HMW forms of adiponectin [10].
Osteoarthritis (OA) is the most common form of chronic
arthritis yet little is known about its aetiopathogenesis. The
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sion of structural changes in OA are multiple and complex. It
is believed that OA is a consequence of mechanical and
biological events that destabilize the normal coupling of
degradation and synthesis within articular joint tissues. The
disease process affects not only the articular cartilage but also
the entire joint structure including the subchondral bone,
ligment, cartilage, capsule, synovial membrane, and periarti-
cular muscles [11,12]. Obesity has been strongly implicated
as a possible risk factor for the development of knee, hip, and
perhaps hand OA [13–15]. It has been suggested that
increased joint loading resulting from obesity would increase
the risk of developing knee and hip OA. At this stage, it is
difficult to arrive at an explanation for why obesity would be
associated with hand OA. More recently, it has been reported
that obesity could have a systemic metabolic effect that
influences the development of OA [16]. One recent study has
also suggested that another adipocytokine leptin may act as a
regulator of chondrocyte metabolism [17]. While these results
are groundbreaking, more data will be important to further
substantiate the role of obesity in the modulation of metabolic
processes in OA. The present study is an extension to the
above work and reports the significance of adiponectin in
countering the development of OA.
2. Materials and methods
2.1. Patient samples
The characteristics of the study subjects are summarized in Table 1. Blood
sample only or both blood sample and synovial fluid (SF) were obtained from
patients with knee OA. SF samples from 13 patients with rheumatic arthritis
(RA) and 12 patients with gouty arthritis (GA) were also included. SF and
synovial tissue samples were prepared as previously described [18,19].
Patients with OA were selected according to the criteria developed by
American College of Rheumatology [20,21]. The knee radiographs taken
from hospital records were evaluated by two independent orthopedists.
Kellgren–Lawrence criteria [22] were used for classification and grading of
OA, and reliability was tested against Ahlback criteria [23]. The clinical
severity of OA ranged from I to V, with grade I being the least severe and
grade V the most severe. Synovial tissues, cartilage, and bone were obtained
during surgery from patients with OA (n=4) and from subjects with bone
fractures (n=2) who served as controls. Tissue samples were obtained from
the diseased knee and hip joints. All patients were from Taipei Medical
University Hospital. The Research Ethics Board at the Taipei Medical
University approved the use of all specimens.Table 1
Physical and biochemical characteristics of OA patients
Plasma SF Female
plasma
Male
plasma
n 26 24 19 7
Age (years) 65.4±10.8 60.9±14 63.7±10.5 70±10.8
BMI
(kg/m2)
25.8±3.1 25.2±3.4 25.5±3.5 26.8±1.6
Adiponectin 5.3±1.3
(μg/ml)
0.044±0.017
(ng/ml)
5.7±2.8
(μg/ml)
4.3±1.9
(μg/ml)
(1.3∼12.7) (19.4∼97.7) (1.3∼12.7) (1.5∼6.9)
Note. Values are expressed as means±SD.
Abbreviations: BMI, body mass index; SF, synovial fluid.2.2. Measurement of adiponectin
Adiponectin concentrations in plasma and SF from patients with OA were
measured by using a commercial enzyme-linked immunosorbent assay (Human
Adiponectin ELISA Kit; B-Bridge International Inc., San Jose, CA). The
absorbance was read on an automated ELISA plate reader at 450 nm. Values
were calculated from a standard curve. Patient samples were pre-treated
according to the instructions of the manufacturer. The results are expressed as
means±SD.
2.3. Analysis of oligometric state of adiponectin in plasma and SF
After the preparation of patient samples, the distribution of the oligomeric
state of adiponectin in plasma and SF was determined by gel filtration
chromatography, as described in detail previously [24]. Briefly, human plasma
and SF samples were fractionated in a HiLoad 16/60 Superdex 200 column
(Amersham Pharmacia Biotech) equilibrated with PBS, followed by elution with
PBS at a flow rate of 0.5 ml/min with 1.0-ml fractions. Fractions were analyzed
for the concentration of individual isoforms of adiponectin using ELISA as
described above.
2.4. Generation of chondrocytes from human cartilage and cell culture
Cartilage explants were minced and digested overnight with rotation at
37 °C in Dulbecco's modified Eagle medium (DMEM) containing 1 μg per
ml of bacterial collagenase (Sigma, St. Louis, MO). Cells released by
enzymatic digestion were filtered, washed, and pelleted by centrifugation.
Primary human chondrocytes were cultivated in DMEM/F12 medium
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 2 mM L-
glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin at 37 °C in a
humidified atmosphere of 5% CO2. All culture media and reagents were
purchased from GIBCO BRL (Grand Island, NY) unless otherwise stated. For
all experiments, primary chondrocytes were used at passages 3 to 7.
2.5. Measurement of cytokine release using antibody arrays
Primary chondrocytes were starved overnight in serum-free DMEM/F12,
and pretreated with recombinant full-length human adiponectin (R&D Systems,
Minneapolis, MN; 30 μg/ml) for 18 h and subsequently with recombinant
human IL-1 β (R&D Systems, Minneapolis, MN; 5 ng/ml) for 6 h. Following
treatments, the supernatants were collected and assayed for angiogenesis-related
cytokines using the Human Angiogenesis Antibody Array I (RayBiotech,
Aurora, CO) consisting of 20 different cytokine antibodies spotted in duplicate
onto a membrane. Array experiments were performed according to the
manufacturer's instructions.
2.6. RNA preparation and RT-PCR analysis
Total RNAwas extracted from freshly isolated synovial tissue, cartilage, and
bone of OA patients and normal subjects as well as from primary chondrocytes
using TRIzol Reagent (Gibco/BRL, Grand Island, NY). Tissue samples were
obtained from surgery and were frozen by liquid nitrogen. Before treating with
TRIzol Reagent, the frozen tissues were ground and homogenized. The
sequences of the sense and anti-sense primers are listed in Table 2. RT-PCR was
performed with BD Advantage 2 PCR Enzyme System (BD Biosciences
Clontech). The RT-PCR reaction was carried out in a 25-μl volume containing
25–50 ng of cDNA template, 10 pmol of each sense and anti-sense primers for a
specific cDNA, and 2.5 μl 10× Advantage 2 PCR Buffer, 0.25–0.5 μl 50×
Advantage 2 Polymerase Mix, 1 μl 10 mM dNTP mix, and sterile water. For
MMP3, the PCR program consisted of 35 cycles of 94 °C for 45 s, 60 °C for
45 s, and 72 °C for 2 min. For MMP13, the amplification cycles were 95 °C for
1.5 min, 55 °C for 2 min, and 72 °C for 3 min for 35 cycles. For GAPDH, the
amplification cycles consisted of 30 cycles of 94 °C for 45 s, 55 °C for 45 s, and
72 °C for 1 min. For AdipoR1 and AdipoR2, the conditions were 95 °C for
5 min, followed by 30 cycles of 15 s at 95 °C, 1 min at 60 °C, and 1 min at 72 °C.
For T-cadherin, the conditions were 94 °C for 5 min, followed by 30 cycles of
30 s at 94 °C, 30 s at 55 °C, and 30 s at 72 °C. For TIMP-1, the conditions were
Table 2
Primer sequences
Forward Reverse
AdipoR1 5′-TCTTCCTCATGGCTGTGATG-3′ 5′-AGCACTTGGGAAGTTCCTCC-3′
AdipoR2 5′-GGAGCCATTCTCTGCCTTTC-3′ 5′-ACCAGATGTCACATTTGCCA-3′
T-cadherin 5′-TTCAGCAGAAAGTGTTCCATAT-3′ 5′-GTGCATGGACGAACAGAGT-3′
MMP-3 5′-CCTCTGATGGCCCAGAATTGA-3′ 5′-GAAATTGGCCACTCCCTGGGT-3′
MMP-13 5′-GACTTCACGATGGCATTGCTG-3′ 5′-GCATCAACCTGCTGAGGATGC-3′
TIMP-1 5′-CACCCACAGACGGCCTTCTGCAAT-3′ 5′-AGTGTAGGTCTTGGTGAAGCC-3′
GAPDH 5′-GGAGTCAACGGATTTGGT-3′ 5′-GTGATGGGATTTCCATTG-3′
AdipoR1= adiponectin receptor 1; AdipoR2= adiponectin receptor 2; MMP= matrix metalloproteinase; TIMP-1= tissue inhibitor of metalloproteinase 1.
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PCR amplifications were preceded by an initial denaturation for 5 min at the
given temperature, followed by a final extension cycle at 72 °C for 10 min. The
PCR products were analyzed by agarose (1.5%) gel electrophoresis and
visualized by ethidium bromide staining.
2.7. Statistical analysis
Data were analyzed by SAS (Statistical Analysis System, version 8.0, SAS
Institute Inc., North Carolina, USA). Differences (between experimental groups)
were analyzed by Student's unpaired t test, and linear regression model was
used to examine the relationship between selected variables. P<0.05 was
accepted for statistical significance.Fig. 1. Adiponectin levels in SF from different arthritis patients. SF samples
obtained from patients with RA (n=13), GA (n=12), or OA (n=24) were
analyzed for adiponectin expression by ELISA as described in Materials and
methods. Values are mean±SD and the statistically significant differences are
indicated as comparing with OA samples.3. Results
3.1. Adiponectin expression in OA patients
In order to test our hypothesis that adiponectin plays an
important role in osteoarthritis (OA), plasma and synovial
fluids (SF) from patients with knee OA were assayed for
adiponectin using ELISA. OA plasma exhibited significantly
elevated levels of adiponectin (5.3±1.3 μg/ml; mean±SD,
n=26) as compared with OA SF (44±17 ng/ml; mean±SD,
n=24). We found approximately a 100-fold decrease of
adiponectin in OA SF compared with that in OA plasma.
Results of biochemical characteristics are summarized in Table
1. It also shows that mean adiponectin concentration was lower
in the male group (4.3±1.9 μg/ml; mean±SD, n=7) than in
female group (5.7±2.8 μg/ml; mean±SD, n=17). Moreover,
SF samples from patients with gouty arthritis (GA) and
rheumatic arthritis (RA) were also analyzed for adiponectin
and the results are shown in Fig. 1. It shows a mean of
56.61 ng/ml (n=13) and 67.09 ng/ml (n=12) for GA and RA,
respectively. Compared with OA SF, adiponectin levels were
significantly higher in the SF from patients with GA (P=0.04)
and RA (P=0.006). We further investigated whether a
relationship existed between body mass index (BMI) and
plasma adiponectin levels, and a significant negative correlation
(r=−0.5, P=0.01) was observed in Fig. 2A. An inverse
correlation was also noted between plasma and SF concentra-
tions of adiponectin in OA patients, although the results did not
reach statistical significance (r=−0.37, P=0.14; Fig. 2B).
We assessed whether any relationship existed between
adiponectin levels and OA severity. The Kallgren–LawrenceX-ray grading system was used to determine the severity of
knee OA, and reliability was tested against Ahlback criteria.
Fig. 3 shows a negative correlation between SF adiponectin
levels and the clinical severity of OA, despite the lack of
statistical significance. However, no evident correlation was
found between plasma adiponectin levels and severity of OA
(data not shown).
To further study the possibility that adiponectin is associated
with OA, we examined the distribution and abundance of the
adiponectin isoforms in plasma and SF from patients with OA.
To do this, we exploited the use of gel filtration chromatography
followed by ELISA. The chromatographic profiles of the
adiponectin complexes in plasma and SF are shown in Fig. 4. In
agreement with previous studies, plasma adiponectin yielded
three distinct peaks corresponding to adiponectin high mole-
cular weight (HMW) species, hexamer, and trimer, respectively.
In comparison, peaks representing the adiponectin multimers in
the SF of representative OA patients were not well separated
under similar conditions (Fig. 4A). Furthermore, the ratio of
each oligomeric form of adiponectin to total adiponectin levels
was assessed in SF and plasma from patients with OA (n=4,
Fig. 4B). Compared with OA plasma, OA SF demonstrated a
significantly decreased percentage of adiponectin HMW form
but contained a markedly higher percentage of adiponectin
trimer form per total levels of adiponectin.
Fig. 2. Adiponectin expression in OA patients. (A) Plasma adiponectin levels
expressed in relation to subject BMI. (B) Relation between SF adiponectin
levels and log plasma adiponectin in OA patients.
Fig. 4. Analysis of oligomeric states of adiponectin in OA plasma and synovial
fluid. (A) Elution profiles of adiponectin fractionated on a gel filtration column.
Patient samples for analysis were prepared as described under Materials and
methods, loaded into a HiLoad 16/60 Superdex 200 column, and eluted in PBS.
The gel filtration fraction numbers are indicated. An aliquot of each fraction was
subjected to ELISA system (B). The content of adiponectin HMW, hexamer, and
trimer is expressed relative to the total amount of adiponectin. Statistically
significant differences are indicated.
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To assess the contribution of adiponectin receptors 1 and 2
(AdipoR1 and AdipoR2) to OA, we examined the gene
expression patterns in OA joint tissues by RT-PCR. The
identity of PCR products for each gene was confirmed by DNA
sequencing. As can be noted in Fig. 5, AdipoR1 was markedly
expressed in OA bone, cartilage, and synovial tissues except inFig. 3. Relation between SF adiponectin levels and the severity of OA.one of the bone and synovial tissue samples whereas AdipoR2
was not detected in any of these tissue samples. Normal
synovial tissues expressed both AdipoR1 and AdipoR2, with
AdipoR1 being the predominant form. Interestingly, normal
cartilage expressed only AdipoR1 while normal bone rarely
expressed AdipoR1 and AdipoR2. We also assessed the
expression levels of another adiponectin receptor T-cadherin
in the joint tissues of OA patients. Results showed that T-
cadherin was expressed only in normal synovial tissue among
all of the diseased and normal tissues analyzed (data not
shown).
3.3. Effects of adiponectin on chondrocytes
Inflammation and angiogenesis are closely integrated
processes in OA and may affect disease progression and pain
[25]. In an attempt to rapidly identify the angiogenic cytokines
that may be affected by adiponectin, human angiogenesis
antibody array systems were utilized to detect cytokine release
Fig. 5. Expression of AdipoR1 and AdipoR2 mRNA in OA bone, cartilage, and
synovial tissues. Adiponectin receptors 1 and 2 mRNA levels were analyzed by
RT-PCR using cDNA prepared from OA tissue RNA. The number for each
patient is listed above the bracket. R1 and R2, adipoR1 and adipoR2,
respectively. Representative results from 3 experiments are shown.
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subsequent exposure to IL-1 β. As noted in Fig. 6, four
angiogenesis-related cytokines were detected on membrane
arrays containing 20 different cytokine antibodies. IL-1β
stimulated the production of growth-related oncogene (GRO),
interleukin-6 (IL-6), and monocyte chemoattractant protein-1
(MCP-1). IL-6 was the cytokine most predominantly produced
whereas GRO and MCP-1 were present at relatively lowerFig. 6. Protein microarrays of cytokines secreted by human primary chondrocytes afte
with or without 30 μg/ml adiponectin in the presence or absence of 5 ng/ml IL1β. Th
of this array is shown in panel B.levels. Adiponectin alone likewise stimulated the production of
GRO and MCP-1, but its presence also induced detectable level
of tissue inhibitor of metalloproteinase-2 (TIMP-2). Adiponec-
tin, unlike IL-1 β, did not affect IL-6 secretion and was unable
to suppress IL-1 β induced up-regulation of protein production
of IL-6, GRO, and MCP-1.
Because adiponectin exhibits the ability to up-regulate
TIMP-2 expression in primary chondrocytes, we further
determined whether adiponectin affects the expression of
TIMP-1 and matrix metalloproteinase (MMP) family members
such as MMP-3 and MMP-13. As can be seen in Fig. 7,
treatment with adiponectin alone in primary chondrocytes did
not alter the expression levels of MMP-3, MMP-13, and TIMP-
1. In comparison, pretreatment with adiponectin was able to
partially block IL-1 β-induced MMP-13 gene expression. The
production of MMP-3 and TIMP-1 was otherwise unaffected by
adiponectin.
4. Discussion
Adiponectin is a newly discovered hormone secreted by
adipocytes. Pervious investigations have focused attention on
the effects of adiponectin in glucose homeostasis, insulin
sensitivity and vascular inflammatory diseases [26,27]. Here,
we intended to study whether adiponectin might act as a
protective role in the development of OA. We first determined
the concentrations of plasma and SF adiponectin as well as the
distribution and abundance of the adiponectin complexes in
patients with OA. Moreover, our results clearly showed ther exposure to adiponectin. (A) Chondrocytes were treated in serum-free medium
e respective media were used to detect cytokine release. The comprehensive map
Fig. 7. Effects of adiponectin on MMP13, MMP3, and TIMP-1 mRNA
expression in human primary chondrocytes. Confluent chondrocytes were
treated for 24 h with 30 μg/ml adiponectin and subsequently with 5 ng/ml IL1β
for 24 h Total RNA was collected for analysis as described in Materials and
methods. Lanes: 1, adiponectin only; 2, untreated control; 3, IL1β only; 4, IL1β
and adiponectin. Representative results from 3 experiments are shown.
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we determined whether adiponectin modulates the biologic
effects of primary chondrocytes by using RT-PCR and antibody
arrays. These experiments demonstrated that adiponectin could
alter the expression levels of several genes including GRO,
MCP-1, MMP-13, and TIMP-2. Taken together, these findings
reinforce our concept that adiponectin may play a potential
protective role in the progression of OA.
Prior study has published data showing the mean plasma
concentration of adiponectin in men and women to be 7.2 μg/ml
(Age, 44.5±9.3 years; mean±SD; BMI, 22.9±2.2; mean±SD;
n=198) and 13.4 μg/ml (Age, 41.7±9.7 years; mean±SD;
BMI, 20.6±2.4; mean±SD; n=221), respectively [28]. The
results presented in this study also revealed that there was a
sexual dimorphism in plasma adiponectin in OA patients, with
females (mean=5.7 μg/ml) having considerably higher circu-
lating levels than men (mean=4.3 μg/ml). In addition, the
adiponectin levels in OA SF were found significantly lower
than in OA plasma. It is interesting that an inverse correlation
was noted between plasma and SF concentrations of adipo-
nectin in OA patients. Moreover, despite the lack of statistical
significance, there was a negative correlation of SF adiponectin
levels with the clinical severity of OA. Similar trends have been
observed in a balloon-injured rat carotid artery model described
by Okamoto et al. Their results showed that adiponectin
accumulated in the arterial walls of the injured vessels but not in
non-injured walls, suggesting the potential role of adiponectin
in protecting against atherosclerosis [29]. Besides, the SF
adiponectin levels in patients with GA and RA were analyzed
and compared with OA SF. The mean of adiponectin
concentration in OA SF was significantly lower in the SF
from patients with GA and RA. This finding is in agreement
with a previous report which showed that SF concentrations of
adiponectin were significantly higher in patients with RA than
that in those with OA (mean: 2.2 vs. 1.1 μg/ml, respectively,
P=0.03). Collectively, these findings indicate that adiponectin
may exert a modulator to suppress the progression of arthritis
since its expression is higher in the “inflammatory arthritis”
such as RA and GA.The distribution of the oligomeric species of adiponectin
present in plasma and SF from OA patients were characterized
by using gel filtration chromatography. As assessed by ELISA,
Fig. 4B shows that the mean percentage of the HMW species
per total adiponectin in OA plasma was approximately 50%,
which was slightly lower than control subjects with a previously
stated value of 55% [24]. By comparison, the trimer form of
adiponectin in OA SF was significantly higher than in OA
plasma. Taeda et al. have reported that adiponectin transcript
was not expressed in cartilage tissue by RT-PCR analysis [30].
We also found that chondrocyte and synoviocyte cell lines were
not expressed adiponectin transcript (data not shown). It is
possible that a major source of OA SF adiponectin is from blood
and that the low molecular weight form of adiponectin is readily
transferred into the SF in OA joint. Since excessive fat in SF has
been shown to induce arthritic changes in patients with OA [31],
fat cells may also be one of the adiponectin producers in SF.
Kobayashi et al. have established a possible link between
different distribution of the adiponectin isoforms and some
human diseases, and the percentage of HMW per total
adiponectin has been shown to be significantly lower in patients
with coronary artery disease than control subjects [24]. Studies
by Pajvani et al. have found that complex distribution, not
absolute amount of circulating adiponectin, is critical in
determining thiazolidinedione-mediated improvements in insu-
lin sensitivity [32]. In this study, RT-PCR analyses showed that
AdipoR1 was expressed in all OA and normal tissues tested
except in normal bone, and normal synovial tissues expressed
AdipoR2 and T-cadherin transcripts. AdipoR1 and AdipoR2
isoforms have been shown to serve as receptors for adiponectin
and mediate the fatty-acid oxidation and increase in PPAR-α
ligand activity [7]. T-cadherin has recently been reported to act
as a receptor that directly binds the hexamer and HMW forms
but not the trimer form of adiponectin [10]. Then maybe it is
possible that different distribution of the adiponectin complexes
and the presence of adiponectin receptors contribute to the
activity of different signaling events in OA joint tissues.
However, further research will be necessary to characterize
which oligomeric forms of the adiponectin in plasma and SF
from patients with OA are responsible for the protective role in
arthritis.
During OA, the progressive degradation of articular
cartilage leads to joint dysfunction, disability, and pain.
Erosion of cartilage matrix is thought to be a local imbalance
in the proteinases/inhibitors content. The main enzymes
involved in matrix breakdown are MMPs and the MMPs
activity is partially inhibited by TIMPs [33,34]. Previous
study has found that adiponectin has an ability to increase
TIMP-1 expression through IL-10 induction in human
macrophages [35]. In the present study, we showed that
pretreatment of primary chondrocytes with adiponectin was
able to up-regulate TIMP-2 expression and partially abolish
IL-1β-induced MMP-13 expression. These results suggest
that adiponectin may be involved in the joint metabolism by
altering the balance of MMPs and TIMPs. It also since
adipnectin has been found with the ability to suppress the
LPS-induced NFκB signaling [36], the suppression of IL-1β-
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NFκB pathway as well. Numerous experimental studies have
indicated that adiponectin possesses several anti-inflammatory
activities, which include the suppression of leukocytic colony
formation, reduction of phagocytic activity, and reduction of
TNFα and IL-6 production in macrophages [36,37]. Contrary
to early claims, this study demonstrated that treatment of
primary chondrocytes with recombinant adiponectin could
only up-regulate the gene expression of MCP-1 and GRO just
like the effects evoked by IL-1β. Moreover, pretreating
primary chondrocytes with adiponectin for 18 h did not
appear to suppress the IL-1β-induced production of IL-6,
GRO, and MCP-1. Therefore, it may be reasonable to
postulate that functionally different types of cells may
contribute to the distinct anti-inflammatory effects exerted
by adiponectin. Additional investigations to test this hypoth-
esis are warranted.
It has been established for some time that obesity represents
a large risk factor for OA. Alterations in lipid metabolism have
been reported to be involved in the diversity of physiological
changes in generalized OA [16]. However, very little experi-
mental evidence exists to support this. The present work appears
to be the first demonstration of a protective role of adiponectin
against OA. We showed that adiponectin, a newly discovered
adipocytokine, may be one of the important factors involved in
the molecular events that prevent the development of OA.
Future studies are required to fully understand the molecular
mechanisms responsible for the decreased adiponectin produc-
tion in OA, as well as for the anti-inflammatory activities of
adiponectin in osteoarthritic joints. Investigations on the clinical
significance of adiponectin in normal and pathological
processes of OA may provide potential therapeutic targets for
disease treatment.
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